Effect of food and tablet-dissolution characteristics on the bioavailability of a linagliptin fixed-dose combination with metformin: Evidence from two randomized trials

International Journal of Clinical Pharmacology and Therapeutics

Volumn 52, Issue 7, 2014, Pages 549-563

  Metzmann, Katrin ^a   Schnell, David ^b   Jungnik, Arvid ^a   Ring, Arne ^a,c,d   Theodor, Rudolf ^e   Hohl, Kathrin ^a   Meinicke, Thomas ^a   Friedrich, Christian ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b SocraMetrics GmbH   (Germany)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d UNIVERSITY OF THE FREE STATE   (South Africa)

^e ClinPharm Reform GmbH   (Germany)

Author keywords

Fixed dose combination; Linagliptin; Metformin; Type 2 diabetes

Indexed keywords

LINAGLIPTIN PLUS METFORMIN;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CYSTITIS; DIARRHEA; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; FATIGUE; FOOD; FOOD DRUG INTERACTION; HEADACHE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MORNING DOSAGE; OROPHARYNX PAIN; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUG COMBINATIONS; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PURINES; QUINAZOLINES; SOLUBILITY; TABLETS;

EID: 84903990834     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201961     Document Type: Article

References (36)

1. Inzucchi SE, BergenstaI RM, Buse JB, Diamant M, Ferrannini E, Nauck M. Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35: 1364-1379. CrossRef PubMed.
2. Rodbard HIV, Jellinger PS, Davidson J A, Einhorn D, Garher AJ. Grunberger G, Handelsman K Horton ES. Lebovitz H, Levy P. Moghissi ES, Schwartz SS. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control. Endocr Pract. 2009; 15: 540-559. CrossRef PubMed.
3. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients. J Int Med Res. 2002; 30: 71-79. CrossRef PubMed. (Pubitemid 34618725)
4. Donnan FT, MacDonald TM. Morris AD. Adherence to prescribed oral hypoglycaemic medica- Tion in a population of patients with Type 2 diabetes: A retrospective cohort study. Diabet Med. 2002; 19: 279-284. CrossRef PubMed. (Pubitemid 34592152)
5. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin Ther. 2001; 23: 1311-1320. CrossRef PubMed. (Pubitemid 32804123)
6. Blonde L, Wogen J, Kreilick C, Seymour A A. Greater reductions in A1C in type 2 diabetic pa- Tients new to therapy with glyburide/metformin tablets as compared to glyburide co- Administered with metformin. Diabetes Obes Metab. 2003; 5: 424-431. CrossRef PubMed. (Pubitemid 37483604)
7. Cheong C, Barrier JC, Lawson KA, Johnsrud MT. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther. 2008; 30: 1893- 1907. CrossRefPubMed.
8. Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: A comparison of monotherapy, combination therapy, and fixed- dose combination therapy. Clin Ther. 2002; 24: 460-467. CrossRef PubMed. (Pubitemid 34275867)
9. Pan F, Chemew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med. 2008; 23: 611-614. CrossRef PubMed.
10. Kawamori R, Inagaki N, Araki E, Watada H, Hayashi N, Horie Y, Sarashina A, Gong Y, von Eynatten M, Woerle IU. Dugi KA. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: A randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab. 2012; 14: 348-357. CrossRef PubMed.
11. Del Prato S, Burnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: A randomized controlled trial. Diabetes Obes Metab. 2011; 13: 258-267. CrossRef PubMed.
12. Forst T, Uhlig-Laske B, Ring A, Graefe-Mody U, Friedrich C, Herbcich K, Woerle HJ, Dugi KA. Linagliptin (BI 1356), a potent and selective DPP- 4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabet Med. 2010; 27: 1409-1419. CrossRefPubMed.
13. Gallwitz B, Rosenstoek J, Ranch T, Bhattacharya S, PateIS, von Eynatten M Dugi KA, Woerle HJ. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: A randomised, double-blind, non-inferiority trial. Lancet. 2012: 380: 475-483. CrossRef PubMed.
14. Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: A randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2012; 14: 565-574. CrossRef PubMed.
15. Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: A 24- week randomized study. Diabet Med. 2011; 28: 1352-1361. CrossRef PubMed.
16. Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA, Woerle HJ. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011; 13: 65-74. CrossRef PubMed.
17. Ross SA, Rafeiro E, Meinieke T, Toorawa R, Weber-Bom S, Woerle HJ. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5mg once daily in patients with type 2 diabetes inadequately controlled on metformin: A randomised, double-blind, placebo-controlled trial. Curr Med Res Opin. 2012; 28: 1465-1474. CrossRef PubMed.
18. Bristol-Myers Squibb Company. Glucophage® (metformin hydrochloride) Tablets, Glucophagc® XR (metformin hydrochloride) Extended-Release Tablets. Available at: http://packageinserts.bms.com/pi/piglucophage.pdf. Last accessed August 16, 2013.
19. Singh BN. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet. 1999; 37: 213-255. CrossRef PubMed. (Pubitemid 29452756)
20. Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm. 2004; 58: 265-278. CrossRef PubMed. (Pubitemid 39037234)
21. European Medicines Agency. Trajenta: EPAR Public assessment report. Available at: http://www.ema.europa.eu/docs/en-GB/docuttient-library/EPAR- Publicassessmentreport/human, 002110/WC500115748.pdf. Last accessed August 16, 2013.
22. U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER). Guidance for Industry: food-effect bioavailability and fed bioequivalcncc studies. Available at: http:/www.fda.gov/downloads/regulatoryinformation/guidances/uem126833.pdf. Last accessed August 16, 2013.
23. Graefe-Mody EU, Padula S, Ring A. Withopf B, Dugi KA. Evaluation of the potential for steady- state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin. 2009; 25: 1963-1972. CrossRef PubMed.
24. U.S. Depart men t of Health and Human Services FaDA, Centre for Drug Evaluation and Research (CDER). Guidance for industry: bioanalytical method validation. Available at: http://www.fda.gov/downloadsDrugs/Guidances/ucm070107. pdf. Last accessed August 16, 2013.
25. U.S. Department of Health and Human Services FaDA, Centre for Drug Evaluation and Research (CDER). Guidance for industry: bioavailability and bioequivalence studies for orally administered ding products- general considerations. Available at: http://www.fda.gov/downloads.Drugs/Guidance- CompIianeeRegulatoryInformation/Guidances/ucm070124.pdf Last accessed August 16, 2013.
26. (EMEA) EMA. Guideline on the Investigation of Bioequivalence. Available at: http://www.ema.europa.eu/docs/enGB/documentlibrary/Scientific-guideline/ 2010/01AVC500070039.pdf Last accessed August 16, 2013.
27. Graefe-Mody U, Giessmann T, Ring A, lovirto M, Woerle HJ, A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects. Clin Ther, 2011; 33: 1096-1103. CrossRef PubMed.
28. Sambol NC, Brookes LG, Chiang J, Goodman AM, Lin FT, Liu CY, Benet LZ. Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCI in man, Br J Clin Pharmacol, 1996; 42: 510-512. CrossRef PubMed. (Pubitemid 26340155)
29. Kcirini A, Slater M, Bradford D, Schwartz L, Laurent A, Oral antidiabetic drugs: effect of food on absorption of pioglitazone and metformin from a fixed-dose combination tablet. J Clin Pharmacol. 2007; 47: 48-55. CrossRef PubMed. (Pubitemid 44973997)
30. Marathe PH, Arnold ME, Meeker J, Greene DS, Barhhaiya RH. Pharmacokinetics and bioavailability of a metformin/glyburide tablet administered alone and with food. J Clin Pharmacol. 2000; 40: 1494-1502. PubMed.
31. He YL, Flannery B, Campestrini J, Leon S, Zinny MA, Ligueros-Saylan M, Jarugula V. Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers. Curr Med Res Opin. 2008; 24: 1703-1709. CrossRef PubMcd. (Pubitemid 351929068)
32. Dandona P, Fonseea V, Mier A, Beckett AG. Diarrhea and metformin in a diabetic clinic. Diabetes Care. 1983; 6: 472-474. CrossRef PubMed. (Pubitemid 13005555)
33. Garber A J, Duncan TG, Goodman A M, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997; 103: 491- 497. CrossRef PubMed. (Pubitemid 28018651)
34. Kahn SE, Haffner SM, Heise MA, Herman WH, Hoiman RR, Jones NP, Kravin BG, Lachin JM, O'Neill MC, Zinman B, Viherti G; ADOPT Study Group. Glycemie durability of rosiglitazone, met-formin, or glyburide monotherapy. N Engl J Med. 2006; 355: 2427-2443. CrossRef PubMed. (Pubitemid 44903747)
35. Boehringer Ingelheim International GmbH, Jenta-dueto™ (linagliptin and metformin hydrochloride) tablets. Available at: http://www.accessdata.fda, gov/drugsatfdadocs/label/2012/201281sOOOlbl, pdf. Last accessed August 16, 2013.
36. Boehringer Ingelheim International GmbH. Jen- Taduento - 2.5 mg/850 mg film-coated tablets; 2.5 mg/1, 000 mg film-coated tablets, linagliptin/metformin hydrochloride. Available at: http://www.medicines.org.uk/LMC/medicine/27018/ P1L/Jentadueto+2.5+mg+85ofmg+film-coated+tablets+and+Jentadueto+2. 5+mg+1%2e000+mg+film-coatcd-ftablets/. Last accessed August 16, 2013.